Catalyst Pharmaceutical Partners, Inc. today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will present at the Piper Jaffray 26th Annual Healthcare Conference held at The New York Palace Hotel in New York City, Dec. 2-3. The presentation is scheduled for Tuesday, Dec. 2 at 12:00 p.m. EST. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=885310

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/581,187. The patent application is generally directed to methods reducing visual field defects and intramyelinic edema resulting from the use of a GABA-aminotransferase inhibitor by using CPP-115, a new and novel GABA-AT inactivator, to treat neurological or psychological disorders.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=884518

 

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. reported financial results for the third quarter and nine months ended September 30, 2014.

Read the full release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=883057

 

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. announced that it has entered into a memorandum of understanding (“MOU”) to settle its pending class action securities lawsuit.

Read the full release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=880228

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. announced the appointment of David J. Caponera to the newly created position, vice president, patient advocacy and reimbursement, effective immediately. Mr. Caponera will report to David D. Muth, executive vice president, corporate development.

Read the full release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=878590

 

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

The Agenda is included below or read the full release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=878271

Agenda: “New Advances in the Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)”

  • Clinical Features and Pathophysiology of Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndrome (CMS)
    Perry Shieh, MD, PhD
    Associate Professor
    Director, Neuromuscular Program
    UCLA Medical Center
  • Electrodiagnosis and Management of LEMS
    Yuen So, MD, PhD
    Professor of Neurology
    Chief, Neurology Clinic
    Stanford University Medical Center
  • Initial Firdapse Pivotal Phase 3 Study Safety Results
    Mazen Dimachkie, MD
    Professor of Neurology
    University of Kansas Medical Center
  • Initial FirdapsePivotal Phase 3 Study Efficacy Results
    Shin J. Oh, MD
    Distinguished Professor Emeritus
    University of Alabama at Birmingham Medical Center
  • Serving the LEMS Patient – Firdapse Expanded Access Program
    Charles Gorodetzky, MD, PhD
    Chief Medical Officer
    Catalyst Pharmaceuticals

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. today announced that Douglas Winship, Vice President of Regulatory Operations, will present top-line safety and efficacy results from Catalyst’s Phase 3 FirdapseTM trial at the 139th Annual Meeting of the American Neurological Association being held at The Baltimore Waterfront Marriott, October 12-14. The presentation, entitled, “A Phase 3 Trial of Firdapse™ Tablets in Lambert-Eaton Myasthenic Syndrome,” to be delivered at the Neuromuscular Disease Special Interest Symposia, is scheduled for Sunday, October 12th at 5:20 pm (EDT).

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=875162

 

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will present at the 13th Annual BIO Investor Forum being held at The Palace Hotel in San Francisco, California, October 7-8.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=874272

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment
  • Treatment with Firdapse achieved statistical significance for both co-primary clinical endpoints
  • Catalyst expects to initiate rolling NDA submission in early-2015
  • Conference call tomorrow, September 30 at 8:30am EDT

Catalyst Pharmaceutical Partners, Inc., (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced positive top-line results from the pivotal Phase 3 clinical trial of Firdapse™ (amifampridine phosphate tablets equivalent to 10 mg amifampridine) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). Both co-primary endpoints, quantitative myasthenia gravis score (QMG) and subject global impression (SGI), demonstrated that Firdapse was significantly superior to placebo, as did a secondary endpoint for the physician’s clinical global impression of improvement (CGI-I).

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=873552

 

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. announced the appointment of David D. Muth to the newly created position, Executive Vice President, Corporate Development. Mr. Muth will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst. As Executive Vice President, Corporate Development, Mr. Muth will be responsible for all of Catalyst’s corporate development activities and will work closely with the other members of the Catalyst team in preparing a commercialization strategy for Firdapse™.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=869114

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment
Follow

Get every new post delivered to your Inbox.

Join 213 other followers

%d bloggers like this: